RELMADA THERAPEUTICS, INC. — Investor Relations & Filings
Filings indexed
579
across all filing types
Latest filing
2026-04-09
Prospectus
Country
US
United States of America
Listing
US
RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 424B3 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer) | 2026-04-09 | English | |
| 8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer) | 2026-03-20 | English | |
| SCHEDULE 13G Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-12 | English | |
| 424B5 Filing | 2026-01-30 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
6 filings
| |||||
| 33936661 | 424B3 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer) | 2026-04-09 | English | ||
| 33002503 | 8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer) | 2026-03-20 | English | ||
| 30531824 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 30531823 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30531820 | SCHEDULE 13G Filing | 2026-02-12 | English | ||
| 30531821 | 424B5 Filing | 2026-01-30 | English | ||
|
2025
9 filings
| |||||
| 12579753 | Director's Dealing 2025 | 2025-12-16 | English | ||
| 12579754 | Director's Dealing 2025 | 2025-12-16 | English | ||
| 12579755 | Director's Dealing 2025 | 2025-12-16 | English | ||
| 12579756 | Director's Dealing 2025 | 2025-12-16 | English | ||
| 12579757 | Director's Dealing 2025 | 2025-12-16 | English | ||
| 12579758 | Director's Dealing 2025 | 2025-12-16 | English | ||
| 12579759 | Director's Dealing 2025 | 2025-12-16 | English | ||
| 12579760 | CURRENT REPORT | 2025-12-15 | English | ||
| 12579761 | Major Shareholding Notification 2025 | 2025-11-15 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
RELMADA THERAPEUTICS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34465/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34465 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34465 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34465 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34465}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for RELMADA THERAPEUTICS, INC. (id: 34465)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.